News & Investors

Latest press announcements, recognitions, events and investor updates from Dianosic.

Latest news

All Awards Company Events Invest Partners

Apr 23, 2020

FINSMES x Dianosic

Apr 23, 2020

Finyear x Dianosic – funding

Apr 23, 2020

Next Finance x Dianosic

Apr 23, 2020

Hospital and Healthcare Management x Dianosic

Apr 23, 2020

Industrie Mag x Dianosic

Apr 23, 2020

Maddyness x Dianosic

They support us

Our investors

We built a solid network of partners to support company funding and growth.

Wiseed

Bpi France

Fondation Force

Eurométropole de Strasbourg

Banque Populaire Rives de Paris

Caisse d’épargne Grand Est

La Région Grand Est

Stay updated

Subscribe to our quarterly newsletter for the latest news on our pipeline, scientific publications and investor updates.

DIANOSIC

Biotech · Paris & Strasbourg · Founded 2017

Reinventing drug delivery via the intranasal route

Dianosic develops complex intranasal formulations and advanced drug-delivery solutions for chronic respiratory diseases and central nervous system disorders.

Key highlights

Cutting-edge platform of intranasal, long-acting solid dosage forms

The DIAXX insert delivers a targeted, low dose of drug in a controlled manner for up to 12 months.

Significant potential across respiratory and neurological indications

Chronic allergic rhinitis (8M), chronic rhinosinusitis (5M) and CNS diseases via Nose-to-Brain delivery (Schizophrenia, Parkinson — 23M) represent large adressable markets.

Solving a critical adherence challenge

50% of patients do not adhere to their medications across therapeutic areas. Our "insert and forget" approach guarantees 100% adherence.

€7M raised in 2025 — led by Aptar Pharma

Series A round with Aptar (Global drug delivery leader), Noshaq, Capital Grand Est and Finovam Gestion to accelerate clinical development.

A complementary team

In-house Pharma and Medtech expertise supported by a Scientific Board composed of world-renowned experts.

contact@dianosic.com